A UC Berkeley spinout startup is developing a one-time gene therapy using transposons (jumping genes) to sustain GLP-1 activity for lasting weight loss effects1.
This approach aims to replace the need for daily GLP-1 injections like those in current weight loss drugs1.
The news highlights innovative gene delivery for obesity treatment, distinct from recent genetic studies on GLP-1 drug responses23.
Sources:
1. https://www.longevitytoday.com/articles/uc-berkeley-startup-uses-jumping-genes-to-deliver-lasting-glp-1-weight-loss-ther-web-modyj8mv
2. https://www.sciencenews.org/article/glp-1-weight-loss-genetics-side-effects
3. https://www.statnews.com/2026/04/08/23andme-genetic-changes-weight-loss-glp1/